# A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients

> **NCT02088060** · PHASE2 · TERMINATED · sponsor: **Central Institute of Mental Health, Mannheim** · enrollment: 150 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Cannabidiol
- **DRUG:** Olanzapine
- **DRUG:** Placebo Cannabidiol
- **DRUG:** Placebo Olanzapine

## Key facts

- **NCT ID:** NCT02088060
- **Lead sponsor:** Central Institute of Mental Health, Mannheim
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12-08
- **Primary completion:** 2024-09-16
- **Final completion:** 2024-09-16
- **Target enrollment:** 150 (ESTIMATED)
- **Why stopped:** Following the expiry of the original research grant, no follow-up financing could be provided to complete the study.
- **Last updated:** 2024-12-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02088060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02088060, "A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02088060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*